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Background: Pneumococcal and Haemophilus influenzae type b (Hib) vaccines were introduced in our national
immunisation program in April 2010. The aims of this retrospective, laboratory-based study were to determine the
serotypes and antibiotic resistance of Streptococcus pneumoniae and H. influenzae isolates from middle ear fluid
(MEF) collected before the introduction of immunization.
Methods: S. pneumoniae (n = 128) and H. influenzae (n = 40) strains isolated from MEF of children with AOM
between 1994 and 2011 were studied. MICs were determined by a microdilution assay. Serotyping of S.
pneumoniae was done by Quellung method and PCR capsular typing was used for H. influenzae. Macrolide
resistance genes were detected by PCR for erythromycin resistant S. pneumoniae (ERSP). DNA sequencing of ftsI
gene was performed for ampicillin nonsusceptible H. influenzae.
Results: The most common serotypes found among children with pneumococcal AOM were 19 F (20.3%), 6B
(15.6%), and 19A (10.9%). The potential coverage rates by the PCV7, PCV10 and PCV13 of children aged < 5 years
were 63.6%, 66.4% and 85.5%, respectively. Reduced susceptibility to oral penicillin was seen in 68.1%; resistance to
erythromycin was 46.9%. We found erm(B) gene in 56.7% of the ERSP, mef(E) gene in 25%; 15% harbored both
genes erm(B) +mef(E) and 3.3% had mutations of L4 ribosomal protein. Of the 40 H. influenzae isolates 97.5% were
nontypeable. Nonsusceptibility to ampicillin occurred in 25%. Ampicillin resistance groups were: β-lactamase
-positive ampicillin resistant (BLPAR) strains (10%), β-lactamase-negative ampicillin resistant (BLNAR) strains (12.5%)
and β-lactamase-positive amoxicillin-clavulanate resistant (BLPACR) strains (2.5%). Among BLNAR and BLPACR most
of the isolates (5/6) belonged to group II, defined by the Asn526Lys substitution.
Conclusions: The levels of antibiotic resistance among S. pneumoniae and H. influenzae causing severe AOM in
children are high in our settings. The existence of multidrug-resistant S. pneumoniae serotype 19A is of particular
concern. The rate of BLNAR and BLPACR strains among H. influenzae isolates was 15%.
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Acute otitis media (AOM) is the most common infection
in children and the most common reason for which antibi-
otics are prescribed in this age group [1]. Currently, Strepto-
coccus pneumoniae along with nontypeable Haemophilus
influenzae are the major pathogens of AOM cases [2,3].
In a study of bacterial etiology of AOM between 2009
and 2010 in Bulgaria, the most frequently isolated
pathogen was S. pneumoniae (47.6%), followed by H.
influenzae (27.6%) [4].
Among the 93 pneumococcal serotypes, only a few are
responsible for most cases of AOM in children world-
wide, including serotypes 3, 6A, 6B, 9V, 14, 19A, 19F,
and 23F [5,6]. Three pneumococcal conjugate vaccines
(PCVs) are currently licensed for use in children and
they have showed modest efficacy against AOM overall
[7]. The 7-valent PCV was widely used throughout the
world in the past 10 years. Recently, two new PCVs were
introduced since 2010, PCV10 (Synflorix; GSK, UK) and
PCV13 (Prevenar 13; Pfizer, USA). In children aged < 5
years with AOM, the PCV7, PCV10 and PCV13 covered
54%, 60% and 85% of the pneumococcal serotypes,
respectively in Germany [8].
Vaccination against pneumococcal diseases with PCV10
was introduced in Bulgaria in our national immunization
program (NIP) for the first time in April, 2010. PCV7 was
not used in Bulgaria prior to PCV10 introduction. Add-
itionally, H. influenzae type b (Hib) conjugate vaccine was
also included for routine immunization of infants as part
of a pentavalent vaccine since 1 st April, 2010. Both conju-
gate vaccines are free of charge.
The prevalence of antibiotic-resistant S. pneumoniae
has increased globally before the pre-vaccine era. The
pattern of changes in antimicrobial susceptibility varies
among serotypes and geographic regions [9]. Prior to
PCV7 introduction, the major problem with antimicro-
bial resistance in S. pneumoniae worldwide was non-
susceptibility to penicillin, macrolides and multidrug
resistance [10].
Resistance to β-lactams in H. influenzae, especially to
ampicillin/amoxicillin, ranging from 3 to 65% in some
countries is an increasing problem [11]. Although, ampi-
cillin resistance is predominantly mediated by the β-
lactamase production, alterations in penicillin-binding
proteins (PBPs), mainly PBP 3, due to ftsI amino acid
substitutions occur in some parts of the world [12]. In
addition, β-lactamase positive, amoxicillin-clavulanate
-resistant strains have been described due to the com-
bination of both mechanisms [13].
The objectives of our study were to determine sero-
types and antibiotic susceptibility of S. pneumoniae and
H. influenzae isolates from middle ear fluid (MEF)
cultures collected before the introduction of conjugate
vaccines in the NIP. The presence of macrolideresistance determinants in S. pneumoniae isolates and
the prevalence of mechanisms of ampicillin resistance in
H. influenzae strains were also studied.
Methods
Patients and isolates
Pediartic (< 14 years of age) S. pneumoniae (n = 128)
and H. influenzae (n = 40) isolates from middle ear fluid
cultures obtained from children with the clinical diag-
nosis “acute otitis” complicated with otorrhea were
examined. The AOM episodes were confirmed by an
otorrinolaryngologist or pediatrician. The strains were iso-
lated from several microbiological laboratories throughout
Bulgaria between 1994 and 2011 and isolates had been
sent in our department on a voluntary basis through a
passive, laboratory-based study for retrospective ana-
lysis. Only one episode of AOM or one isolate of any
of the two pathogens was included per patient, except for
one child from whom both were detected from the same
sample (mixed infection). Serotypes of S. pneumoniae
were distributed per age group (≤ 2 years, 2–5 years,
and >5-14 years); 90% of H. influenzae strains were
isolated from children aged less than 5 years. None of
the children with AOM had been immunized with
pneumococcal or Hib conjugate vaccines. Five pneumo-
coccal strains isolated in 2011 were also included
because they were from children which had not re-
ceived vaccines.
S. pneumoniae strains were confirmed with both
methods - optochin susceptibility test and bile solubility.
H. influenzae isolates were identified by Gram-stain
morphology, growth requirements for factor V, X, and
porphyrin (A.L.A. disks, Remel, Lenexa, Kansas, USA),
biochemical tests according to standard methods and
the presence of iga protease gene determined by conven-
tional PCR [14,15].
Antimicrobial susceptibility test
The antibiotic susceptibilities were determined by the
broth microdilution method according to guidelines of
Clinical and Laboratory Standards Institute (CLSI) [16].
Minimal inhibitory concentrations (MICs) were performed
on Microtiter plates (Sensititre, Trek Diagnostic Systems
Ltd., UK). STR6F MIC plate was inoculated with cation-
adjusted Mueller-Hinton broth and 5% lysed horse blood
for S. pneumoniae, and for H. influenzae HPB-Haemophi-
lus/Streptococcus pneumoniae plate was inoculated with
Haemophilus test broth. Final bacterial density was 5 ×
105 CFU/ml and the plates were incubated at 35°C for
20–24 h in 5% CO2. The MICs were interpreted according
to CLSI, 2010 [16]. All H. influenzae strains were tested for
β-lactamase production by the chromogenic cephalosporin
test with nitrocefin as substrate. Standard quality control
strains were S. pneumoniae ATCC 49619 and H. influenzae
Table 1 Serotype distribution of S. pneumoniae isolates
from children with acute otitis media by age group and
potential vaccine coverige: 1994-2011




≤ 2 y > 2–5 y ≤ 5 y > 5 y - 14 y
PCV7 serotypes
19 F 17 7 24 2 26 (20.3)
6 B 8 9 17 3 20 (15.6)
14 10 - 10 1 11 (8.6)
9 V 5 3 8 3 11 (8.6)
23 F 5 4 9 1 10 (7.8)
18 C 1 1 2 1 3 (2.3)
Total no. 46 24 70 11 81 (63.3)
Other vaccine serotypes
19 A 9 4 13 1 14 (10.9)
3 2 3 5 1 6 (4.7)
6 A 1 2 3 1 4 (3.1)
7 F 1 1 2 - 2 (1.6)
1 - 1 1 1 2 (1.6)
Total no. 13 11 24 4 28 (21.9)
Non-vaccine serotypes
15 B 2 3 5 - 5 (3.9)
23 A 2 1 3 - 3 (2.3)
11a - 2 2 - 2 (1.6)
13,28b - 1 1 1 2 (1.6)
15 C - 2 2 - 2 (1.6)
10a 1 1 2 - 2 (1.6)
16/36/37b - - - 1 1 (0.8)
24/31/40b - 1 1 - 1 (0.8)
NTc - - - 1 1 (0.8)
Total no. 5 11 16 3 19 (14.8)
Overall
no. (%)
64 (50.0) 46 (35.9) 110 (85.9) 18 (14.1) 128 (100.0)
Percentage coverage rate of pneumococcal conjugate vaccines
PCV7 71.9 52.2 63.6 61.1 63.3
PCV10 73.4 56.5 66.4 66.7 66.4
PCV13 92.2 76.1 85.5 83.3 85.2
a The strains were determined to serogroup.
b Expected to be serotypes/serogroups (Strains were positive only for one of
the pooled sera).
c Non-typeable strains with Pneumotest-kit sera.
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were defined as multidrug resistant (MDR).
Serotyping
Serogrouping of S. pneumoniae was performed using the
latex agglutination method (Pneumotest-Latex kit, Statens
Serum Institut, Copenhagen, Denmark). Serotyping was
performed later with the capsular Neufeld Quellung
method by using some common factor antisera (SSI,
Copenhagen, Denmark) [17]. H. influenzae strains were
serotyped by a PCR capsule typing method, detecting the
capsule-producing gene - bexA. The algorithm used for
detection of the cap genes and for determining capsular
serotypes was that proposed by Falla et al. [18].
Detection of macrolide resistance determinants in S.
pneumoniae
The presence of erm(B) and mef(A) was evaluated concur-
rently in a duplex reaction by PCR for all erythromycin-
resistant S. pneumoniae (ERSP) isolates. The primer sets
were as described by Sutcliffe et al. [19]. Gene amplifica-
tion was performed using a Techgene-thermal cycler
(Techne, England). Mef(A) and mef(E) were then distin-
guished by PCR restriction fragment length polymorphism
analysis of the 348-bp mef amplicon with BamHI restric-
tion enzyme (New England Biolabs), which has no restric-
tion site in mef(E) and one in mef(A), generating two
fragments of 284 and 64 bp [20]. Mutations in ribosomal
protein L4 were determined as described elsewhere [21].
DNA sequencing analysis of ftsI gene in H. influenzae
The DNA fragment encoding the transpeptidase region
of PBP 3 was amplified by PCR from strains which were
nonsusceptible to ampicillin (MICs of ≥ 2 μg/ml). Ampli-
fication of ftsI gene was done using primers and PCR
conditions described previously [22]. Nucleotide and
amino acid sequences were analysed using DNAMAN
4.11 Software (Lynnon BioSoft, Canada). Deduced amino
acid sequences were compared with the reference
sequence obtained from the H. influenzae Rd strain.
Strain ATCC 49247 was included as an H. influenzae
BLNAR control strain.
We classified H. influenzae strains according to their
ampicillin susceptibility, β-lactamase production, and on
the basis of the DNA sequencing results obtained from
ampicillin-nonsusceptible isolates. Four main classes were
determined: β-lactamase negative, ampicillin-susceptible
strains with MIC of ≤ 1 μg/ml (BLNAS); strains producing
β-lactamase, and without mutations in the ftsI gene
(BLPAR); β-lactamase negative, ampicillin-nonsusceptible
strains (MICs of ≥ 2 μg/ml) which have amino acid substi-
tutions in the ftsI gene (BLNAR); and isolates that have
both mechanisms (β-lactamase production and amino
acid substitutions in the ftsI gene)(BLPACR).Results
Serotype distribution among S. pneumoniae and H.
influenzae
Serotypes of 128 S. pneumoniae isolates obtained from
MEF are presented in Table 1. The strains are divided in
three age groups: children aged < 2 years (50.0%), children
aged >2 to 5 years (35.9%), and children aged > 5 y - 14 y
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pneumococcal AOM was 19 F (20.3%), followed by sero-
types 6B (15.6%), 19A (10.9%), serotypes 14 and 9 V (8.6%
each), and 23 F (7.8%). Serotypes 19A, 3 and 6A included
in the PCV13 accounting altogether 18.7% among
pneumococcal strains.
Coverage by serotypes included in the current PCV
was evaluated and the calculations were performed with-
out accounting for possible cross-protection. The poten-
tial coverage rates by the PCV7, PCV10 and PCV13 for
children aged < 5 years were 63.6%, 66.4% and 85.5%,
respectively.
Forty MEF isolates from children with AOM were
identified as H. influenzae. Nontypeable H. influenzae
(NTHi) strains predominated (n = 39; 97.5%), and one
was encapsulated serotype a isolate (2.5%).
Antimicrobial susceptibility
Antibiotic susceptibility data for 128 S. pneumoniae isolates
are presented in Table 2. Reduced susceptibility to penicil-
lin (oral penicillin V) was seen in 68.1% of the strains. This
included strains (28.1%) with high level of resistance to
penicillin (MIC ≥ 2 mg/L). The rate of resistance to
macrolides (erythromycin) was 46.9%. Susceptibility results
to amoxicillin shows 6.2% intermediately resistant strains
and 4.7% fully resistant isolates. In a pre-vaccine era
the percentage of multidrug-resistant strains was 53.9%
(69/128). In order to observe any changes in antibiotic
resistance over the time, all pneumococcal strains were
divided in two periods depending on the year when the
strain was isolated: 1994–2005 and the more represen-
tative pre-vaccine period 2006–2011 (Table 2). During
the second period we revealed increased resistance to
erythromycin from 36.7% to 53.2%, and to clindamycin
from 22.4% to 40.5%, respectively. Non-susceptibilityTable 2 Antimicrobial susceptibility of 128 S. pneumoniae isol
nonsusceptibility divided in two periods depending on year o
Antibiotics MICs (μg/mL) Overall% susceptibility n
MIC50/90 MIC range S I
Penicillin 0.12/4.0 0.01 - 8.0 31.2 40.6 28
Amoxicillin 0.12/4.0 0.01 - 8.0 89.1 6.2 4.7
Cefuroxime sodium ≤0.5/8.0 ≤0.5-≥ 16.0 63.3 5.5 31
Ceftriaxone 0.06/1.0 0.03-4.0 93.0 4.7 2.3
Erythromycin ≤0.25/≥64.0 ≤0.25-≥ 64.0 53.1 0.0 46
Clindamycin 0.06/≥64.0 0.01-≥ 64.0 66.4 0.8 32
Levofloxacin 1.0/1.0 0.5 - 2.0 100.0 0.0 0.0
Tetracycline 2.0/≥8.0 0.25-≥ 8.0 50.8 0.8 48
Chloramphenicol 4.0/≥8.0 0.5-≥ 8.0 84.4 - 15
Trimeth/Sulfameth 2.0/≥4.0 0.06-≥ 4.0 35.2 22.7 42
MICs-minimal inhibitory concentracions; MIC50/90, MICs for 50% and 90% of the isola
according to CLSI, 2010); NS - nonsusceptibility; The following breakpoints (μg/mL)
0.12 - 1.0; resistant ≥ 2; Trimethoprim/Sulfamethoxazole (1:19 ratio), MIC refers to trirates to amoxicillin, cefuroxime sodium and ceftriaxone
were found in 8.2%, 28.6% and 4.1%, respectively in the
first period, and were increased up to 12.7%, 41.8% and
8.9%, respectively in the second period 2006–2011.
A total of 40H. influenzae strains were tested for
susceptibility to antibiotics. High-nonsusceptibility rates
were found to trimethoprim-sulfamethoxazole - 35.0%
(14/40), and to ampicillin - 25.0% (10/40). Of the 10
ampicillin nonsusceptible H. influenzae strains, 9 were
fully resistant to ampicillin (MIC ≥ 4 mg/L) and one was
intermediately susceptible (MIC = 2 mg/L) isolate
(Table 3). Ceftriaxone and levofloxacin were the most
active agents tested, and all isolates were fully suscep-
tible to these agents.
Macrolide resistance determinants among S. pneumoniae
isolates
Of the 128 MEF isolates 60 (46.9%) were ERSP. The dis-
tribution of macrolide resistance determinants and par-
ticular serotypes are presented in Table 4. We found erm
(B) gene in 34 isolates (56.7%), mef(E) gene in 15 isolates
(25.0%), 9 isolates harbored both genes erm(B) +mef(E)
(15.0%), and 2 (3.3%) strains had mutations of L4 riboso-
mal protein. The predominant serotypes among erm(B)
genotype were 6B (n = 16), 19A (n = 9), and 19 F (n = 6).
Of the 15 isolates harboring mef(E) gene the prevalent
serotypes were 14 (n = 10) and 19 F (n = 3). The dual re-
sistance mechanism erm(B) +mef(E) was found in 19 F
(n = 7) and 19A (n = 2) serotypes. Of note, resistance
mechanism L4 found in two strains isolated in 1995 has
never been seen in the years after. The coverage rates of
the PCV7, PCV10 and PCV13 for ERSP were 75.0%,
75.0% and 96.7%, respectively. Considering co-resistance
rates to penicillin according to macrolide resistance
genotype, the percentage of strains exhibiting non-ates from middle ear fluids and trends in antibiotic
f strain isolation












tes, respectively; R-resistant; I-intermediate; S-susceptible (Interpretation
for penicillin (oral penicillin V) were used: susceptible ≤ 0.06; intermediate ≥
methoprim value.
Table 3 Distribution of ampicillin resistance classes of paediatric middle ear fluids H. influenzae isolates according to
their β-lactamase production, susceptibilities to ampicillin and amoxiclav, and amino acid substitutions present in
ampicillin nonsusceptible strains with mutations in ftsI gene
Resistance
class
No. of strains (%) β-lac MIC (mg/L) Amino acid substitution(s) in ftsI gene Group
Ampicillin Amoxiclav
BLNAS 30 (75.0) - ≤ 1.0 ≤ 2.0 ND -
BLPAR 4 (10.0) + ≥ 8.0 ≤ 2.0 No changes -
BLNAR 1 (2.5) - 4.0 4.0 Arg517His I
BLNAR 1 (2.5) - 2.0 4.0 Asn526Lys IIa
BLPACR 1 (2.5) + ≥ 8.0 4.0 Asp350Asn, Gly490Glu, Asn526Lys, Ala530Ser IIa
BLNAR 2 (5.0) - 4.0 8.0 Asp350Asn, Met377Ile, Gly490Glu, Ala502Val, and Asn526Lys IIb
BLNAR 1 (2.5) - 4.0 8.0 Asp350Asn, Ala502Thr, Asn526Lys IIc
Total 40 (100.0)
Abbreviations: β-lac, β-lactamase production; Amoxiclav, amoxicillin-clavulanic acid (2:1 ratio). MIC refers to amoxicillin value. ND, DNA sequencing of ftsI gene was
not done; BLNAS, β-lactamase negative, ampicillin-susceptible strains; BLPAR, β-lactamase positive ampicillin-resistant H. influenzae without amino acid
substitutions in the PBP 3; BLNAR, β-lactamase negative ampicillin-resistant H. influenzae with amino acid substitutions in the PBP 3; BLPACR, β-lactamase positive
strains with amino acid substitutions in the PBP 3; No changes along the section of amino acids 350 to 530. The strains with ftsI gene mutations were classified
into groups according to the proposed criteria by Dabernat et al. [22].
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found in 93.3% of ERSP isolates overall. The proportion
of fully resistant to penicillin ERSP isolates was 17.6% in
strains harboring erm(B) gene, 20.0% in these carried
mef(E) gene, whereas 66.7% of isolates showing the dual
resistance mechanism erm(B) +mef(E) were fully resist-
ant to oral penicillin.
Ampicillin-resistant mechanisms and amino acid
substitutions of PBP 3 among MEF H. influenzae isolates
The total collection of 40H. influenzae was grouped
according to our definition of ampicillin resistance clas-
ses: BLNAS strains (n = 30; 75.0%), BLPAR (n = 4; 10.0%)
isolates without mutations in the ftsI gene, BLNAR
strains (n = 5; 12.5%) with amino acid substitutions in
the ftsI gene, and BLPACR (n = 1; 2.5%) strain that was
β-lactamase positive, and had mutations in the critical
region of ftsI gene with amino acid substitutions in PBP 3.
Table 3 shows these ampicillin-resistance classes according
to their β-lactamase production, susceptibilities to
ampicillin and amoxicillin-clavulanic acid, and amino acidTable 4 Genotype distribution of 60 erythromycin-resistant S







erm(B) 34 (56.7) 6 (17.6) 25 (73.5
mef(E) 15 (25.0) 3 (20.0) 11 (73.3
erm(B) +mef(E) 9 (15.0) 6 (66.7) 3 (33.3)
L4
2 2 (3.3) 2 (100.0) -
Total no. (%) of ERSP 60 (46.9) 17 (28.3) 39 (65.0
R-resistant; I-intermediate; S-susceptible (Interpretation according to CLSI, 2010); 1Th
susceptible ≤ 0.06; intermediate ≥ 0.12 - 1.0; resistant ≥ 2. 2 Mutations in ribosomal psubstitutions which present in ampicillin nonsusceptible
strains. Of note, among six strains with amino acid
substitutions in PBP 3 (5 BLNAR and one BLPACR),
three were resistant to amoxicillin-clavulanic acid,
and three strains were susceptible according to CLSI
breakpoints.
The nucleotide sequences of the ftsI gene were deter-
mined for 10 ampicillin-nonsusceptible H. influenzae
strains (MICs ≥ 2 μg/ml) and their deduced amino acid
sequences were compared with those of the ampicillin-
susceptible Rd strain. Five β-lactamase nonproducing
strains had significant amino acid substitutions in the
ftsI gene, thereby we categorizing them as BLNAR
strains. Among remaining 5 β-lactamase positive strains,
one isolate had amino acid substitutions in PBP 3.
According to the classification of Dabernat et al. [22]
different mutation patterns were identified among
BLNAR and BLPACR strains. The Arg517His substitu-
tion that defines group I was observed in one ampicillin
nonsusceptible H. influenzae. Most isolates (n = 5) belonged
to group II, defined by the Asn526Lys substitution, and. pneumoniae (ERSP) isolates from middle ear fluids:
nicillin1 n (%) Serotypes of ERSP (n)
S
) 3 (8.8) 6B (16); 19A (9); 19 F (6); 14, 23 F, 23A (1) each
) 1 (6.7) 14 (10); 19 F (3); 6B, 15B (1) each
- 19 F (7); 19A (2)
- 19A (2)
) 4 (6.7) -
e following breakpoints (μg/mL) for penicillin (oral penicillin V) were used:
rotein L4 were determined as described elsewhere [21].
Setchanova et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:6 Page 6 of 8
http://www.ann-clinmicrob.com/content/12/1/6could be further subdivided into three subgroups - IIa, IIb
and IIc. Group III mutations in ftsI gene conferring high-
level resistance were not detected.Discussion
This is a retrospective study about serotype distribution
and antibiotic resistance of MEF S. pneumoniae and H.
influenzae isolates collected from children before intro-
duction of PCV10 and Hib conjugate vaccines nationwide.
Microbiological diagnosis of AOM is not done on a rou-
tine basis in Bulgaria and this mild disease is underrepre-
sented in our data set. Also, the tympanocentesis is not a
common practice in our country. Thus, bacterial cultures
studied here most likely represent cases of severe otitus
media or patients with a complicated AOM.
The analysis included 128 S. pneumoniae isolates, of
which 86% occurring in children aged ≤ 5 years. We
found a relatively high rate of serotype 19F infections
(20.3%), which is in accordance with the serotype distri-
bution observed in the studies of AOM in German chil-
dren [8], and the Finland [7]. Serotypes 6B and 19A
were next most prominent, each comprising about 16%
and 11%, respectively of the overall data set. The cover-
age calculations for the serotypes included in PCV7
without cross-protection was 63.6% in children with
AOM aged < 5 years, which is almost the same as was
the serotype coverage previously reported for invasive
pneumococcal disease (IPD) for the same age group in
Bulgaria [23]. The PCV10 increase the coverage by 2.8%
of pneumococcal AOM (66.4%). The PCV13, which
includes three serotypes in addition to the PCV10,
would increase the coverage to 85.5%, mainly due to
serotype 19A followed by serotypes 3 and 6A (Table 1).
However the cross-protection of serotype 6B towards
serotype 6A was not included in calculations for our
study. We found 14 serotype 19A isolates, 13 of which
were multidrug resistant.
The results showed a high rate of reduced oral penicil-
lin nonsusceptibility (68%) and a very high rate of ERSP
isolates (47%) among MEF strains. These rates are more
than twice as high as previously recorded with IPD iso-
lates in Bulgaria studied during the same year period
[23]. These high resistance rates may be due to clonal
spread of certain MDR pneumococcal serotypes such as
6B, 19 F and 19A. This resistance reflects the complexity
of many of the severe otitis media episodes which included
therapy failures. Notably, we observed that the percentages
of macrolide, clindamycin, amoxicillin, cefuroxime sodium
and ceftriaxone nonsusceptibility increased among S.
pneumoniae strains isolated during the last 6 years of the
study period. The high antibiotic consumption for the
treatment of AOM represents the major pressure for
resistance selection [24].Overall, macrolide resistance in S. pneumoniae now is
mainly due to erm(B) gene ( 71.7%), including 15% of
isolates with a dual macrolide resistance mechanism
(Table 4). This pattern of macrolide resistance determi-
nants in the last years replaced the efflux mechanism of
macrolide resistance (mef genotype), which was predom-
inant among ERSP in Bulgaria before 2005 [25].
Macrolide-resistant S. pneumoniae strains were found to
be co-resistant to oral penicillin (Table 4), and to other
compounds, such as tetracycline and trimethoprim-
sulfamethoxazole (data not shown). Thus, the prevalence
of MLSB genotype may be due to clonal spread of
certain MDR pneumococcal serotypes as 6B, 19 F and
19A. Interestingly, we observed multi-resistant serotype
19A in many years ago. For the first time, this MDR
serotype was found in 1995 with L4 mutations as the
mechanism of macrolide resistance [21]. Since 2000 and
after, erm (B) genotype was found in serotype 19A iso-
lates (nine strains). Dual macrolide resistance mecha-
nisms were observed recently, between 2008 and 2010 in
two serotype 19A strains (Table 1 and Table 4). Both the
emergence of a new clone or capsular switching might
be associated with these changes in our 19A serotype
isolates. A considerable increase in the disease caused by
serotype 19A has been recorded after the introduction
of PCV7 in some countries [24,26]. Of note, MDR sero-
type 19A isolates have also been identified in Israel and
Finland before the large-scale use of conjugate vaccines
as was the case in our study [27,28].
Our findings of 97.5% nontypeable H. influenzae
strains isolated from AOM are in accordance with the
literature [11,29]. Nontypeable H. influenzae are the
major etiologic agents of respiratory tract infections in
our country as was shown before [30]. Ampicillin/
amoxicillin nonsusceptible H. influenzae were found to
be a quarter of our MEF isolates. Among BLNAR and
BLPACR most of the isolates (5/6) belonged to Dabernat
group II, defined by the Asn526Lys substitution. A high
incidence of BLNAR H. influenzae strains has been
reported in Japan, Spain and France [11,12,22]. The
emergence of BLNAR and BLPACR strains among MEF
H. influenzae isolates may have implications for the
treatment of AOM infections, because amoxicillin and
amoxicillin-clavulanate are the most common antibiotics
used in the treatment of AOM in our country.
The main limitations of our study are: 1) it covers a
long period of time, and the power is low; 2) isolates
were sent by microbiology labs in hospitals, and we do
not have clinical information on the type of AOM; 3) as
isolates came from hospitals, they are not representative
of S. pneumoniae and H. influenzae isolates causing oti-
tis in children attending primary medical centers; 4) the
numbers of S. pneumoniae and H. influenzae strains are
small, because only a portion of children with AOM in
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that they may represent a rough estimate of the serotype
distribution and antibiotic resistance among a group of
children with complicated AOM. This information will
be invaluable when planning vaccination strategies to
protect against otitis media.
In conclusion, the levels of antibiotic resistance among
S. pneumoniae and H. influenzae causing severe otitis
media in children are high in our settings. This has im-
portant therapeutic implications because such antibiotic-
resistant isolates compromise the choice of macrolides
and amoxicillin as treatment of AOM episodes in chil-
dren. The existence of MDR S. pneumoniae serotype
19A before the active pneumococcal immunization is of
particular concern. The rate of 15% BLNAR and
BLPACR strains among H. influenzae MEF isolates may
have implications for the treatment of AOM. Ongoing
surveillance is needed for both pathogens in order to
observe any changes in serotypes prevalence and anti-
biotic resistance after introduction of conjugate vaccines
in our country.
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